Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disorders

Journal of Dermatology

Volumn 41, Issue 1, 2014, Pages 29-39

  Park, Sanghui ^a   Ko, Young H ^b  

^a Ewha Womans University School of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Epstein Barr virus; Korea; lymphoma; lymphoproliferative disease; T natural killer cell

Indexed keywords

AGGRESSIVE NK CELL LEUKEMIA; CHILDHOOD DISEASE; CHRONIC ACTIVE EPSTEIN BARR VIRUS INFECTION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HUMAN; HYDROA VACCINIFORME; HYPERSENSITIVITY; INCIDENCE; MOSQUITO BITE; NK T CELL LYMPHOMA; REVIEW; T LYMPHOCYTE; COMPLICATION; EPSTEIN-BARR VIRUS INFECTIONS; LYMPHOPROLIFERATIVE DISORDERS; NOMENCLATURE; VIROLOGY;

EPSTEIN-BARR VIRUS INFECTIONS; HUMANS; INCIDENCE; LYMPHOMA, EXTRANODAL NK-T-CELL; LYMPHOPROLIFERATIVE DISORDERS; TERMINOLOGY AS TOPIC;

EID: 84892684406     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.12322     Document Type: Review

References (114)

1. Swerdlow SH, Campo E, Harris NL, et al,. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC, Lyon 2008.
2. Ko Y, Kim H, Oh Y, et al,. EBV-associated T and NK cell lymphoproliferative disorders: consensus report of the 4th Asian Hematopathology Workshop. J Hematopathol 2012; 5: 319-324.
3. Lee MY, Tan TD, Feng AC, et al,. Clinicopathological analysis of malignant lymphoma in Taiwan, defined according to the World Health Organization classification. Haematologica 2005; 90: 1703-1705.
4. Lymphoma Study Group of Japanese Pathologists. The World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Pathol Int 2000; 50: 696-702.
5. Laurini JA, Perry AM, Boilesen E, et al,. Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases. Blood 2012; 120: 4795-4801.
6. Kim JM, Ko YH, Lee SS, et al,. WHO classification of malignant lymphomas in Korea: report of the third nationwide study. Korean J Pathol 2011; 45: 254-260.
7. Yang QP, Zhang WY, Yu JB, et al,. Subtype distribution of lymphomas in Southwest China: analysis of 6,382 cases using WHO classification in a single institution. Diagn Pathol 2011; 6: 77.
8. Cho EY, Kim KH, Kim WS, et al,. The spectrum of Epstein-Barr virus-associated lymphoproliferative disease in Korea: incidence of disease entities by age groups. J Korean Med Sci 2008; 23: 185-192.
9. Ishida F, Ko YH, Kim WS, et al,. Aggressive natural killer cell leukemia: therapeutic potential of L-asparaginase and allogeneic hematopoietic stem cell transplantation. Cancer Sci 2012; 103: 1079-1083.
10. Kimura H, Hoshino Y, Kanegane H, et al,. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood 2001; 98: 280-286.
11. Ohshima K, Kimura H, Yoshino T, et al,. Proposed categorization of pathological states of EBV-associated T/natural killer-cell lymphoproliferative disorder (LPD) in children and young adults: overlap with chronic active EBV infection and infantile fulminant EBV T-LPD. Pathol Int 2008; 58: 209-217.
12. Ohshima K, Suzumiya J, Sugihara M, et al,. Clinicopathological study of severe chronic active Epstein-Barr virus infection that developed in association with lymphoproliferative disorder and/or hemophagocytic syndrome. Pathol Int 1998; 48: 934-943.
13. Hong M, Ko YH, Yoo KH, et al,. EBV-positive T/NK-cell lymphoproliferative disease of childhood. Korean J Pathol 2013; 47: 137-147.
14. Gu H, Chang B, Qian H, et al,. A clinical study on severe hydroa vacciniforme. Chin Med J (Engl) 1996; 109: 645-647.
15. Iwatsuki K, Satoh M, Yamamoto T, et al,. Pathogenic link between hydroa vacciniforme and Epstein-Barr virus-associated hematologic disorders. Arch Dermatol 2006; 142: 587-595.
16. Iwatsuki K, Xu Z, Takata M, et al,. The association of latent Epstein-Barr virus infection with hydroa vacciniforme. Br J Dermatol 1999; 140: 715-721.
17. Iwatsuki K, Ohtsuka M, Akiba H, et al,. Atypical hydroa vacciniforme in childhood: from a smoldering stage to Epstein-Barr virus-associated lymphoid malignancy. J Am Acad Dermatol 1999; 40: 283-284.
18. Cho KH, Lee SH, Kim CW, et al,. Epstein-Barr virus-associated lymphoproliferative lesions presenting as a hydroa vacciniforme-like eruption: an analysis of six cases. Br J Dermatol 2004; 151: 372-380.
19. Cho KH, Kim CW, Lee DY, et al,. An Epstein-Barr virus-associated lymphoproliferative lesion of the skin presenting as recurrent necrotic papulovesicles of the face. Br J Dermatol 1996; 134: 791-796.
20. Cho JH, Kim HS, Ko YH, et al,. Epstein-Barr virus infected natural killer cell lymphoma in a patient with hypersensitivity to mosquito bite. J Infect 2006; 52: e173-e176.
21. Huh SY, Choi M, Cho KH,. A case of Epstein-Barr virus-associated hydroa vacciniforme. Ann Dermatol 2009; 21: 209-212.
22. Cohen JI, Kimura H, Nakamura S, et al,. Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008. Ann Oncol 2009; 20: 1472-1482.
23. Barrionuevo C, Anderson VM, Zevallos-Giampietri E, et al,. Hydroa-like cutaneous T-cell lymphoma: a clinicopathologic and molecular genetic study of 16 pediatric cases from Peru. Appl Immunohistochem Mol Morphol 2002; 10: 7-14.
24. Chen HH, Hsiao CH, Chiu HC,. Hydroa vacciniforme-like primary cutaneous CD8-positive T-cell lymphoma. Br J Dermatol 2002; 147: 587-591.
25. Rodriguez-Pinilla SM, Barrionuevo C, Garcia J, et al,. EBV-associated cutaneous NK/T-cell lymphoma: review of a series of 14 cases from Peru in children and young adults. Am J Surg Pathol 2010; 34: 1773-1782.
26. Ishihara S, Yabuta R, Tokura Y, et al,. Hypersensitivity to mosquito bites is not an allergic disease, but an Epstein-Barr virus-associated lymphoproliferative disease. Int J Hematol 2000; 72: 223-228.
27. Tokura Y, Ishihara S, Tagawa S, et al,. Hypersensitivity to mosquito bites as the primary clinical manifestation of a juvenile type of Epstein-Barr virus-associated natural killer cell leukemia/lymphoma. J Am Acad Dermatol 2001; 45: 569-578.
28. Asakura K, Kizaki M, Ikeda Y,. Exaggerated cutaneous response to mosquito bites in a patient with chronic lymphocytic leukemia. Int J Hematol 2004; 80: 59-61.
29. Kunitomi A, Konaka Y, Yagita M,. Hypersensitivity to mosquito bites as a potential sign of mantle cell lymphoma. Intern Med 2005; 44: 1097-1099.
30. Ishihara S, Okada S, Wakiguchi H, et al,. Clonal lymphoproliferation following chronic active Epstein-Barr virus infection and hypersensitivity to mosquito bites. Am J Hematol 1997; 54: 276-281.
31. Park S, Bahng S, Kim EK, et al,. Hodgkin's lymphoma arising in a patient with hypersensitivity to mosquito bites: a case report. J Clin Oncol 2010; 28: e148-e150.
32. Chung JS, Shin HJ, Lee EY, et al,. Hypersensitivity to mosquito bites associated with natural killer cell-derived large granular lymphocyte lymphocytosis: a case report in Korea. Korean J Intern Med 2003; 18: 50-52.
33. Roh EJ, Chung EH, Chang YP, et al,. A case of hypersensitivity to mosquito bite associated with Epstein-Barr viral infection and natural killer cell lymphocytosis. J Korean Med Sci 2010; 25: 321-323.
34. Seon HS, Roh JH, Lee SH, et al,. A case of hypersensitivity to mosquito bites without peripheral natural killer cell lymphocytosis in a 6-year-old Korean boy. J Korean Med Sci 2013; 28: 164-166.
35. Yoon TY, Kim YG, Kim JW, et al,. Nodal marginal zone lymphoma in association with hydroa vacciniforme-like papulovesicular eruption, hypersensitivity to mosquito bites and insect bite-like reaction. Br J Dermatol 2005; 153: 210-2125.
36. Quintanilla-Martinez L, Kumar S, Fend F, et al,. Fulminant EBV(+) T-cell lymphoproliferative disorder following acute/chronic EBV infection: a distinct clinicopathologic syndrome. Blood 2000; 96: 443-451.
37. Penman HG,. Fatal infectious mononucleosis: a critical review. J Clin Pathol 1970; 23: 765-771.
38. Henter JI, Horne A, Arico M, et al,. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007; 48: 124-231.
39. Fox CP, Shannon-Lowe C, Gothard P, et al,. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults characterized by high viral genome load within circulating natural killer cells. Clin Infect Dis 2010; 51: 66-69.
40. Kasahara Y, Yachie A, Takei K, et al,. Differential cellular targets of Epstein-Barr virus (EBV) infection between acute EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. Blood 2001; 98: 1882-1888.
41. Kimura H, Ito Y, Kawabe S, et al,. EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood 2012; 119: 673-686.
42. Imashuku S, Hibi S, Tabata Y, et al,. Outcome of clonal hemophagocytic lymphohistiocytosis: analysis of 32 cases. Leuk Lymphoma 2000; 37: 577-584.
43. Lin MT, Chang HM, Huang CJ, et al,. Massive expansion of EBV+ monoclonal T cells with CD5 down regulation in EBV-associated haemophagocytic lymphohistiocytosis. J Clin Pathol 2007; 60: 101-103.
44. Wada T, Kurokawa T, Toma T, et al,. Immunophenotypic analysis of Epstein-Barr virus (EBV)-infected CD8(+) T cells in a patient with EBV-associated hemophagocytic lymphohistiocytosis. Eur J Haematol 2007; 79: 72-75.
45. Chen RL, Su IJ, Lin KH, et al,. Fulminant childhood hemophagocytic syndrome mimicking histiocytic medullary reticulosis. An atypical form of Epstein-Barr virus infection. Am J Clin Pathol 1991; 96: 171-176.
46. Su IJ, Wang CH, Cheng AL, et al,. Hemophagocytic syndrome in Epstein-Barr virus-associated T-lymphoproliferative disorders: disease spectrum, pathogenesis, and management. Leuk Lymphoma 1995; 19: 401-4065.
47. Ahn JS, Rew SY, Shin MG, et al,. Clinical significance of clonality and Epstein-Barr virus infection in adult patients with hemophagocytic lymphohistiocytosis. Am J Hematol 2010; 85: 719-722.
48. Matsuda K, Nakazawa Y, Yanagisawa R, et al,. Detection of T-cell receptor gene rearrangement in children with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis using the BIOMED-2 multiplex polymerase chain reaction combined with GeneScan analysis. Clin Chim Acta 2011; 412: 1554-1558.
49. Ryder J, Wang X, Bao L, et al,. Aggressive natural killer cell leukemia: report of a Chinese series and review of the literature. Int J Hematol 2007; 85: 18-25.
50. Ishihara S, Ohshima K, Tokura Y, et al,. Hypersensitivity to mosquito bites conceals clonal lymphoproliferation of Epstein-Barr viral DNA-positive natural killer cells. Jpn J Cancer Res 1997; 88: 82-87.
51. Suzuki R, Suzumiya J, Nakamura S, et al,. Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells. Leukemia 2004; 18: 763-770.
52. Ko YH, Park S, Kim K, et al,. Aggressive natural killer cell leukemia: is Epstein-Barr virus negativity an indicator of a favorable prognosis? Acta Haematol 2008; 120: 199-206.
53. Kluin PM, Feller A, Gaulard P, et al,. Peripheral T/NK-cell lymphoma: a report of the IXth Workshop of the European Association for Haematopathology. Histopathology 2001; 38: 250-270.
54. Soler J, Bordes R, Ortuno F, et al,. Aggressive natural killer cell leukaemia/lymphoma in two patients with lethal midline granuloma. Br J Haematol 1994; 86: 659-662.
55. Oshimi K,. Progress in understanding and managing natural killer-cell malignancies. Br J Haematol 2007; 139: 532-544.
56. Makishima H, Ito T, Asano N, et al,. Significance of chemokine receptor expression in aggressive NK cell leukemia. Leukemia 2005; 19: 1169-1174.
57. Makishima H, Ito T, Momose K, et al,. Chemokine system and tissue infiltration in aggressive NK-cell leukemia. Leuk Res 2007; 31: 1237-1245.
58. Tani R, Ozaki S, Kosaka M, et al,. Fas ligand-induced apoptosis of hepatocytes in natural killer cell leukaemia. Br J Haematol 1999; 106: 709-712.
59. Lay JD, Tsao CJ, Chen JY, et al,. Upregulation of tumor necrosis factor-α gene by Epstein-Barr virus and activation of macrophages in Epstein-Barr virus-infected T cells in the pathogenesis of hemophagocytic syndrome. J Clin Invest 1997; 100: 1969-1979.
60. Nakashima Y, Tagawa H, Suzuki R, et al,. Genome-wide array-based comparative genomic hybridization of natural killer cell lymphoma/leukemia: different genomic alteration patterns of aggressive NK-cell leukemia and extranodal NK/T-cell lymphoma, nasal type. Genes Chromosom Cancer 2005; 44: 247-255.
61. Siu LL, Chan V, Chan JK, et al,. Consistent patterns of allelic loss in natural killer cell lymphoma. Am J Pathol 2000; 157: 1803-1809.
62. Siu LL, Wong KF, Chan JK, et al,. Comparative genomic hybridization analysis of natural killer cell lymphoma/leukemia. Recognition of consistent patterns of genetic alterations. Am J Pathol 1999; 155: 1419-1425.
63. Kwong YL,. Natural killer-cell malignancies: diagnosis and treatment. Leukemia 2005; 19: 2186-2194.
64. Au WY, Weisenburger DD, Intragumtornchai T, et al,. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 2009; 113: 3931-3937.
65. Pellier I, N'Golet L, Rachieru P, et al,. Disseminated nasal-type natural killer/T-cell lymphoma in a child: a case report. J Pediatr Hematol Oncol 2009; 31: 362-366.
66. Shaw PH, Cohn SL, Morgan ER, et al,. Natural killer cell lymphoma: report of two pediatric cases, therapeutic options, and review of the literature. Cancer 2001; 91: 642-646.
67. Zhang Z, Shi Q, An X, et al,. NK/T-cell lymphoma in a child with hypersensitivity to mosquito bites. J Pediatr Hematol Oncol 2009; 31: 855-857.
68. Ha SY, An J, Park S,. Detection of Epstein-Barr virus-infected lymphoid cells in nasal mucosa or nasopharynx: appearances can be deceptive. Virchows Arch 2013; 462: 391-397.
69. Zhang YC, Sha Z, Yu JB, et al,. Gastric involvement of extranodal NK/T-cell lymphoma, nasal type: a report of 3 cases with literature review. Int J Surg Pathol 2008; 16: 450-454.
70. Huang WT, Chang KC, Huang GC, et al,. Bone marrow that is positive for Epstein-Barr virus encoded RNA-1 by in situ hybridization is related with a poor prognosis in patients with extranodal natural killer/T-cell lymphoma, nasal type. Haematologica 2005; 90: 1063-1069.
71. Sung CO, Ko YH,. Bone marrow is involved in less than 10% of patients with nasal-type NK/T cell lymphoma at initial diagnosis. J Korean Med Sci 2004; 19: 229-233.
72. Wong KF, Chan JK, Cheung MM, et al,. Bone marrow involvement by nasal NK cell lymphoma at diagnosis is uncommon. Am J Clin Pathol 2001; 115: 266-270.
73. Emile JF, Boulland ML, Haioun C, et al,. CD5-CD56+ T-cell receptor silent peripheral T-cell lymphomas are natural killer cell lymphomas. Blood 1996; 87: 1466-1473.
74. Gualco G, Domeny-Duarte P, Chioato L, et al,. Clinicopathologic and molecular features of 122 Brazilian cases of nodal and extranodal NK/T-cell lymphoma, nasal type, with EBV subtyping analysis. Am J Surg Pathol 2011; 35: 1195-1203.
75. Ko YH, Ree HJ, Kim WS, et al,. Clinicopathologic and genotypic study of extranodal nasal-type natural killer/T-cell lymphoma and natural killer precursor lymphoma among Koreans. Cancer 2000; 89: 2106-2116.
76. Lin CW, Lee WH, Chang CL, et al,. Restricted killer cell immunoglobulin-like receptor repertoire without T-cell receptor gamma rearrangement supports a true natural killer-cell lineage in a subset of sinonasal lymphomas. Am J Pathol 2001; 159: 1671-1679.
77. Ng SB, Lai KW, Murugaya S, et al,. Nasal-type extranodal natural killer/T-cell lymphomas: a clinicopathologic and genotypic study of 42 cases in Singapore. Mod Pathol 2004; 17: 1097-1107.
78. Ohsawa M, Nakatsuka S, Kanno H, et al,. Immunophenotypic and genotypic characterization of nasal lymphoma with polymorphic reticulosis morphology. Int J Cancer 1999; 81: 865-870.
79. Pongpruttipan T, Sukpanichnant S, Assanasen T, et al,. Extranodal NK/T-cell lymphoma, nasal type, includes cases of natural killer cell and αβ γδ and αβ/γδT-cell origin: a comprehensive clinicopathologic and phenotypic study. Am J Surg Pathol 2012; 36: 481-499.
80. Huang Y, de Reynies A, de Leval L, et al,. Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. Blood 2010; 115: 1226-1237.
81. Iqbal J, Kucuk C, Deleeuw RJ, et al,. Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies. Leukemia 2009; 23: 1139-1151.
82. Iqbal J, Weisenburger DD, Chowdhury A, et al,. Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic γδ T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro. Leukemia 2011; 25: 348-358.
83. Ko YH, Choi KE, Han JH, et al,. Comparative genomic hybridization study of nasal-type NK/T-cell lymphoma. Cytometry 2001; 46: 85-91.
84. Sun HS, Su IJ, Lin YC, et al,. A 2.6 Mb interval on chromosome 6q25.2-q25.3 is commonly deleted in human nasal natural killer/T-cell lymphoma. Br J Haematol 2003; 122: 590-599.
85. Taborelli M, Tibiletti MG, Martin V, et al,. Chromosome band 6q deletion pattern in malignant lymphomas. Cancer Genet Cytogenet 2006; 165: 106-113.
86. Karube K, Nakagawa M, Tsuzuki S, et al,. Identification of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses. Blood 2011; 118: 3195-3204.
87. Karube K, Tsuzuki S, Yoshida N, et al,. Lineage-specific growth inhibition of NK cell lines by FOXO3 in association with Akt activation status. Exp Hematol 2012; 40: 1005-1015 e6.
88. Huang Y, de Leval L, Gaulard P,. Molecular underpinning of extranodal NK/T-cell lymphoma. Best Pract Res Clin Haematol 2013; 26: 57-74.
89. Iqbal J, Liu Z, Deffenbacher K, et al,. Gene expression profiling in lymphoma diagnosis and management. Best Pract Res Clin Haematol 2009; 22: 191-210.
90. Isobe K, Uno T, Tamaru J, et al,. Extranodal natural killer/T-cell lymphoma, nasal type: the significance of radiotherapeutic parameters. Cancer 2006; 106: 609-615.
91. Kim SJ, Kim BS, Choi CW, et al,. Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type. Ann Oncol 2007; 18: 1382-1387.
92. Bossard C, Belhadj K, Reyes F, et al,. Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 2007; 109: 2183-2189.
93. Kim WY, Jeon YK, Kim TM, et al,. Increased quantity of tumor-infiltrating FOXP3-positive regulatory T cells is an independent predictor for improved clinical outcome in extranodal NK/T-cell lymphoma. Ann Oncol 2009; 20: 1688-1696.
94. Shim SJ, Yang WI, Shin E, et al,. Clinical significance of cyclooxygenase-2 expression in extranodal natural killer (NK)/T-cell lymphoma, nasal type. Int J Radiat Oncol Biol Phys 2007; 67: 31-38.
95. Chan JK, Sin VC, Wong KF, et al,. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood 1997; 89: 4501-4513.
96. Ko YH, Cho EY, Kim JE, et al,. NK and NK-like T-cell lymphoma in extranasal sites: a comparative clinicopathological study according to site and EBV status. Histopathology 2004; 44: 480-489.
97. LeBoit PE, Burg G, Weedon D, Sarasain A,. World Health Organization Classification of Tumours. Pathology and Genetics of Skin Tumours. IARC Press, Lyon 2006.
98. Rezania D, Sokol L, Cualing HD,. Classification and treatment of rare and aggressive types of peripheral T-cell/natural killer-cell lymphomas of the skin. Cancer Control 2007; 14: 112-123.
99. Choi YL, Park JH, Namkung JH, et al,. Extranodal NK/T-cell lymphoma with cutaneous involvement: 'nasal' vs. 'nasal-type' subgroups-a retrospective study of 18 patients. Br J Dermatol 2009; 160: 333-337.
100. Chuang SS, Chang ST, Chuang WY, et al,. NK-cell lineage predicts poor survival in primary intestinal NK-cell and T-cell lymphomas. Am J Surg Pathol 2009; 33: 1230-1240.
101. Kim JH, Lee JH, Lee J, et al,. Primary NK-/T-cell lymphoma of the gastrointestinal tract: clinical characteristics and endoscopic findings. Endoscopy 2007; 39: 156-160.
102. Kim YB, Chang SK, Yang WI, et al,. Primary NK/T cell lymphoma of the testis. A case report and review of the literature. Acta Haematol 2003; 109: 95-100.
103. Huang YH, Wu QL, Zong YS, et al,. Nasopharyngeal extranodal NK/T-cell lymphoma, nasal type: retrospective study of 18 consecutive cases in Guangzhou, China. Int J Surg Pathol 2011; 19: 51-61.
104. Jo JC, Yoon DH, Kim S, et al,. Clinical features and prognostic model for extranasal NK/T-cell lymphoma. Eur J Haematol 2012; 89: 103-110.
105. Kim SJ, Oh SY, Hong JY, et al,. When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type? Ann Oncol 2010; 21: 1058-1063.
106. Na II, Kang HJ, Park YH, et al,. Prognostic factors for classifying extranodal NK/T cell lymphoma, nasal type, as lymphoid neoplasia. Eur J Haematol 2007; 79: 1-7.
107. Ha SY, Sung J, Ju H, et al,. Epstein-Barr virus-positive nodal peripheral T cell lymphomas: clinicopathologic and gene expression profiling study. Pathol Res Pract 2013; 209: 448-454.
108. Chang ST, Liao YL, Lin SH, et al,. NK-cell lymphoma with nodal presentation and expression of cutaneous lymphocyte-associated antigen. Pathol Res Pract 2010; 206: 463-466.
109. Chim CS, Ma ES, Loong F, et al,. Diagnostic cues for natural killer cell lymphoma: primary nodal presentation and the role of in situ hybridisation for Epstein-Barr virus encoded early small RNA in detecting occult bone marrow involvement. J Clin Pathol 2005; 58: 443-445.
110. Kagami Y, Sobue R, Ito N, et al,. Cytotoxic large T-cell lymphoma with fulminant clinical course, CD8+ and CD56- phenotype, and its relation to Epstein-Barr virus: a report of two cases. Int J Hematol 1999; 70: 105-111.
111. Takahashi E, Asano N, Li C, et al,. Nodal T/NK-cell lymphoma of nasal type: a clinicopathological study of six cases. Histopathology 2008; 52: 585-596.
112. Park S, Kim K, Kim WS, et al,. Systemic EBV+ T-cell lymphoma in elderly patients: comparison with children and young adult patients. Virchows Arch 2008; 453: 155-163.
113. Kagami Y, Suzuki R, Taji H, et al,. Nodal cytotoxic lymphoma spectrum: a clinicopathologic study of 66 patients. Am J Surg Pathol 1999; 23: 1184-1200.
114. Attygalle AD, Cabecadas J, Gaulard P, et al. Peripheral T-cell and NK-cell lymphomas and their mimics; taking a step forward-report on the lymphoma workshop of the XVIth meeting of the European Association for Haematopathology and the Society for Hematopathology. Histopathology 2013 doi: 10.1111/his.12251 [Epub ahead of print].